Global /United States /Healthcare /Drug Manufacturers - General /PFE
chevron_leftBack

Pfizer Inc.

PFE
NYSE: PFE Delayed
22.36USD -0.8%
As of 24 April 2025, Pfizer Inc. has a market cap of $126.79B USD, ranking #123 globally and #73 in the United States. It ranks #20 in the Healthcare sector, and #12 in the Drug Manufacturers - General industry.
Global Rank
123
Country Rank
73
Sector Rank
20
Industry Rank
12
Key Stats
Market Cap
$126.79BUSD
Enterprise Value
$174.32BUSD
Revenue (TTM)
$63.63BUSD
EBITDA (TTM)
$23.32BUSD
Net Income (TTM)
$8.03BUSD
EBITDA Margin
37%
Profit Margin
13%
PE Ratio
15.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Albert Bourla open_in_new
Founded
1849
Website
pfizer.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-0.8% 1.4% -15% -14% -22% -15%
Upcoming Earnings
Earnings Date
Tue, Apr 29
Earnings Time
sunny Before Open
EPS Estimate
$0.7000 -15% yoy
Revenue Estimate
$14.27B -4.1% yoy

Markets

Exchange Ticker Price
NYSE
MIC: XNYS
PRIMARY
PFE
Pfizer Inc
ISIN: US7170811035
Shares Out.:
5.671B1 Shares Float: 5.669B2
TV:
SA:
YF:
PFE
GF:
NQ:
PFE
BA:
PFE
MS:
22.36 USD
London Stock Exchange
MIC: XLON
0Q1N
Pfizer Inc
ISIN: US7170811035
TV:
SA:
YF:
GF:
BA:
MS:
22.45 USD
Borsa Italiana
MIC: XMIL
1PFE
Pfizer Inc
ISIN: US7170811035
TV:
SA:
YF:
GF:
BA:
MS:
19.72 EUR
Mexican Bolsa
MIC: XMEX
PFE
Pfizer Inc
ISIN: US7170811035
TV:
SA:
YF:
GF:
BA:
PFE
MS:
439.95 MXN
Deutsche Börse Xetra
MIC: XETR
PFE
Pfizer Inc
ISIN: US7170811035
TV:
SA:
YF:
GF:
BA:
PFE
MS:
19.69 EUR
Cboe Canada
MIC: NEOE
PFE
Pfizer Inc Canadian Depository Receipt
ISIN: CA7170651060
TV:
SA:
YF:
GF:
BA:
PFE
MS:
10.27 CAD
Frankfurt Stock Exchange
MIC: XFRA
PFE
Pfizer Inc
ISIN: US7170811035
TV:
SA:
YF:
GF:
BA:
PFE
MS:
19.74 EUR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Similar Companies

Industry: Drug Manufacturers - General (United States)
Name
Market Cap diff.
Eli Lilly and Co.
LLY
$744.65B
487%
Johnson & Johnson
JNJ
$374.1B
195%
AbbVie Inc.
ABBV
$313.02B
147%
Merck & Co., Inc.
MRK
$198.0B
56%
Amgen Inc.
AMGN
$149.41B
18%
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
Novo Nordisk A/S
NOVO-B
$262.78B
1.73T DKK
107%
Roche Holding AG
RO
$246.36B
204.44B CHF
94%
AstraZeneca PLC
AZN
$213.18B
160.68B GBP
68%
Novartis AG
NOVN
$207.35B
172.07B CHF
64%
Sanofi
SAN
$129.34B
114.13B EUR
2%